Evolocumab
- Generic Name
- Evolocumab
- Brand Names
- Repatha
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1256937-27-5
- Unique Ingredient Identifier
- LKC0U3A8NJ
- Background
Evolocumab is a monoclonal antibody designed for the treatment of hyperlipidemia by Amgen. It is a subcutaneous injection approved by the FDA for individuals on maximum statin therapy who still require additional LDL-cholesterol lowering. It is approved for both homozygous and heterozygous familial cholesterolemia as an adjunct to other first-line therapies....
- Indication
Evolocumab is indicated in adult patients with established cardiovascular disease to reduce the risk of myocardial infarction, stroke, and coronary revascularization. It is also indicated as an adjunct to diet, alone or in combination with other hypolipidemic treatments, in adults with primary hyperlipidemia (and in pediatric patients ≥10 years old with hete...
- Associated Conditions
- Coronary Revascularization, Myocardial Infarction, Stroke, Increases in serum total low-density lipoprotein (LDL)
- Associated Therapies
- -
In Silico Study Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Patients With Established Cardiovascular Disease
- Conditions
- Interventions
- First Posted Date
- 2023-08-03
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 204691
- Registration Number
- NCT05974345
- Locations
- 🇫🇷
Novartis Investigative Site, Rueil-Malmaison, France
Evolocumab Added to Statin Therapy in Symptomatic Intracranial Atherosclerotic Stenosis (EAST-ICAS)
- Conditions
- Interventions
- First Posted Date
- 2023-02-23
- Last Posted Date
- 2023-06-02
- Target Recruit Count
- 80
- Registration Number
- NCT05741086
- Locations
- 🇨🇳
the First affiliated hospital of Nanjing Medical University, Nanjing, Jiangsu, China
Safety and Efficacy of Evolocumab in Ischemic Stroke
- First Posted Date
- 2023-01-25
- Last Posted Date
- 2023-01-25
- Target Recruit Count
- 200
- Registration Number
- NCT05697185
The Safety and Long-Term Clinical Benefit of PCSK9i in STEMI Patients
- First Posted Date
- 2022-10-13
- Last Posted Date
- 2022-10-13
- Lead Sponsor
- Hamad Medical Corporation
- Target Recruit Count
- 350
- Registration Number
- NCT05579418
Impact of Evolocumab on the Antiplatelet Effects of Ticagrelor and Aspirin in Patients With Acute Coronary Syndrome
- Conditions
- Interventions
- First Posted Date
- 2022-06-14
- Last Posted Date
- 2022-06-14
- Target Recruit Count
- 30
- Registration Number
- NCT05418166
- Locations
- 🇨🇳
the first affiliated hospital of Harbin Medical University, Harbin, Heilongjiang, China
EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction
- Conditions
- Interventions
- First Posted Date
- 2022-03-17
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Amgen
- Target Recruit Count
- 6019
- Registration Number
- NCT05284747
- Locations
- 🇺🇸
John Muir Health and Cardiovascular Institute, Concord, California, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Northern Arizona Healthcare Corporation Cardiovascular Institute, Flagstaff, Arizona, United States
The Impact of Pcsk-9 Inhibition on PET CFR in Patients at High CV Risk
- First Posted Date
- 2021-12-10
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT05152888
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLC
- Conditions
- Interventions
- First Posted Date
- 2021-12-03
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Scott Antonia
- Target Recruit Count
- 38
- Registration Number
- NCT05144529
- Locations
- 🇺🇸
Duke Univ. Medical Center, Durham, North Carolina, United States
Impact of PCSK9 Inhibition on Clinical Outcome in Patients During the Inflammatory Stage of the COVID-19
- First Posted Date
- 2021-06-28
- Last Posted Date
- 2023-04-21
- Lead Sponsor
- Collegium Medicum w Bydgoszczy
- Target Recruit Count
- 60
- Registration Number
- NCT04941105
- Locations
- 🇵🇱
Antoni Jurasz University Hospital No. 1, Bydgoszcz, Poland
The PCSK9i Inhibitor Evolocumab - a Surgical Trial of Pharamcodynamics and Kinetics Evaluation
- First Posted Date
- 2021-06-24
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Duke University
- Target Recruit Count
- 32
- Registration Number
- NCT04937413
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.